middl
east
respiratori
syndrom
coronaviru
merscov
first
isol
saudi
arabia
patient
sever
acut
respiratori
diseas
complic
renal
failur
sinc
time
viru
caus
sporad
outbreak
mildtosever
respiratori
diseas
approxim
human
case
report
saudi
arabia
case
occur
first
month
begin
may
larg
hospitalassoci
outbreak
mer
occur
republ
korea
outbreak
korea
result
total
merscov
case
includ
death
largest
outbreak
mer
occur
outsid
arabian
peninsula
outbreak
highlight
risk
intern
dissemin
merscov
continu
risk
nosocomi
infect
septemb
number
confirm
global
case
merscov
infect
report
world
health
organ
case
countri
fatal
result
case
fatal
rate
around
merscov
zoonot
viru
transmit
anim
human
camel
like
serv
princip
host
merscov
nosocomi
infect
common
barrier
nurs
practic
limit
spread
viru
viru
seem
pass
easili
persontoperson
unless
close
contact
occur
human
merscov
infect
typic
caus
lower
respiratori
tract
diseas
pneumonia
common
symptom
includ
fever
cough
sore
throat
myalgia
short
breath
symptom
gastrointestin
complic
renal
failur
also
report
patient
especi
sever
chronic
ill
diabet
system
dissemin
document
locat
circulatori
system
respiratori
tract
studi
present
two
princip
object
first
determin
whether
human
antigen
present
cell
apc
permiss
merscov
infect
second
object
determin
cell
suitabl
appropri
secondari
screen
drug
identifi
effect
continu
cultur
cell
line
macrophag
dendrit
cell
dc
profession
apc
link
innat
adapt
immun
apc
act
first
defens
viral
infect
stimul
immun
surveil
prime
toler
appropri
function
apc
critic
abil
mitig
infect
limit
develop
diseas
apc
abund
respiratori
tract
provid
immun
surveil
respond
local
tissu
inflamm
airway
distal
lung
import
role
apc
mitig
infect
produc
cytokin
stimul
inflammatori
respons
recruit
memori
effector
cell
site
infect
profession
apc
also
import
sourc
type
interferon
type
ifn
signific
bystand
effect
uninfect
neighbor
cell
induc
antivir
state
activ
innat
immun
cell
prime
adapt
immun
current
prophylact
therapeut
option
proven
effect
intervent
infect
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
coronavirus
rapidli
identifi
potenti
therapeut
option
emerg
viral
infect
investig
adopt
approach
screen
exist
licens
drug
efficaci
novel
viral
pathogen
screen
licens
drug
could
expedit
implement
new
medic
countermeasur
provid
avenu
offlabel
use
compound
shown
use
treatment
specif
viral
diseas
number
pharmaceut
agent
potenti
treatment
coronavirus
includ
neurotransmitt
inhibitor
estrogen
receptor
antagonist
kinas
signal
inhibitor
proteinprocess
inhibitor
antiparasit
agent
result
previou
studi
found
toremifen
citrat
tomf
chlorpromazin
cpz
chloroquin
cq
effect
block
merscov
sarscov
infect
vitro
establish
cell
line
vero
huh
cell
establish
cell
differenti
method
gener
larg
amount
monocytederiv
macrophag
mdm
dendrit
cell
mddc
high
qualiti
puriti
evalu
compound
virus
yellow
fever
ebola
virus
address
pharmaceut
efficaci
merscov
infect
primari
cell
critic
block
infect
test
sever
candid
mersantivir
human
mdm
immatur
dendrit
cell
test
compound
includ
tomf
estrogen
receptor
antagonist
cpz
neurotransmitt
inhibitor
cq
antimalari
agent
viral
infectionrel
work
perform
biocontain
laboratori
integr
research
facil
irf
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
use
procedur
process
appropri
facil
agent
studi
staff
perform
work
train
work
biocontain
space
merscov
vero
cell
atcc
obtain
american
type
cultur
collect
atcc
manassa
va
maintain
dulbecco
modifi
eagl
medium
heat
inact
fetal
bovin
serum
fb
follow
manufactur
instruct
whole
blood
apc
isol
acquir
either
nation
cancer
institut
frederick
md
biolog
specialti
corpor
colmar
pa
chlorpromazin
hydrochlorid
ca
chloroquin
diphosph
salt
ca
purchas
millipor
sigma
st
loui
mo
toremifen
citrat
ca
purchas
sequoia
research
product
pangbourn
unit
kingdom
dimethyl
sulfoxid
dmso
millipor
sigma
st
loui
mo
use
solvent
highthroughput
screen
assay
describ
merscov
jordan
strain
genbank
access
kindli
provid
dr
kanta
subbarao
nih
bethesda
md
usa
gabriel
defang
naval
medic
research
unit
cairo
egypt
viru
amplifi
infect
vero
cell
multipl
infect
moi
infect
cell
monitor
microscop
daili
cytopath
effect
visibl
day
postinocul
viruscontain
supernat
harvest
clarifi
centrifug
aliquot
storag
merscov
stock
titer
determin
plaqu
assay
vero
cell
see
human
mdm
mddc
differenti
irf
describ
previous
briefli
monocyt
isol
human
peripher
blood
mononuclear
cell
differenti
mdm
mddc
mdm
differenti
cultur
purifi
monocyt
human
macrophagecoloni
stimul
factor
mcsf
r
system
minneapoli
mn
condit
medium
scgf
research
laboratori
ukyoku
jp
day
gener
mddc
monocyt
suppli
ngml
human
granulocyt
macrophagecoloni
stimul
factor
gmcsf
ngml
interleukin
il
medium
lonza
allendal
nj
contain
heat
inactiv
fb
millipor
sigma
cell
incub
day
chang
medium
everi
second
day
immatur
mddc
harvest
point
stimul
induc
matur
induc
matur
medium
replac
mddc
matur
cocktail
medium
contain
ngml
tumor
necrosi
factor
tnf
ngml
ngml
prostaglandin
ngml
gmcsf
ngml
day
postplat
incub
overnight
cell
collect
phenotyp
assay
mdm
mddc
stain
analyz
mention
previous
mdm
antibodi
panel
contain
antihuman
monoclon
antibodi
specif
fluorescein
hladr
pb
apc
pe
bd
bioscienc
panel
test
mddc
includ
pacif
blue
hla
dr
phycoerythrin
pe
fluorescein
quantum
dot
peridinin
chlorophyl
protein
viabil
determin
use
fixabl
yellow
dead
cell
stain
thermo
fisher
scientif
waltham
analysi
mdm
dc
phenotyp
complet
flow
cytometr
analysi
bd
fortessa
lsr
ii
cytomet
bd
bioscienc
san
jose
ca
usa
result
analyz
use
flowjo
softwar
flowjo
ashland
cell
gate
around
live
singlet
monocyt
popul
addit
cell
surfac
marker
express
determin
base
doubleposit
popul
use
gate
strategi
describ
fig
mdm
mddc
immatur
matur
seed
cell
per
well
plate
incub
overnight
next
day
cell
infect
moi
hour
h
inoculum
remov
cell
wash
twice
phosphatebuff
salin
cultur
medium
cellfre
supernat
collect
aliquot
multipl
microtub
indic
timepoint
frozen
use
titer
viru
stock
cellfre
supernat
collect
kinet
studi
determin
plaqu
assay
vero
cell
test
sampl
dilut
serial
sampl
ad
well
plate
contain
confluent
monolay
vero
cell
plate
incub
h
rock
everi
min
viru
adsorpt
infect
follow
incub
prewarm
semisolid
overlay
tragacanth
fc
millipor
sigma
mix
eagl
minimum
essenti
medium
contain
fb
gentli
ad
cell
plate
incub
day
without
disturb
fix
plate
overlay
aspir
cell
fix
stain
neutral
buffer
formalin
nbf
thermo
fisher
scientif
contain
crystal
violet
fc
millipor
sigma
min
room
temperatur
plate
wash
run
water
airdri
plaqu
enumer
viru
titer
calcul
inflammatori
mediat
express
measur
use
custom
human
cytokin
bead
array
cat
millipor
sigma
billerica
luminex
flexmap
system
equip
xponent
softwar
luminex
austin
tx
cytokin
chemokin
includ
panel
monocyt
chemotact
protein
mcp
macrophag
inflammatori
protein
mip
interferoninduc
protein
ip
regul
upon
activ
normal
tcell
express
secret
rant
assay
perform
accord
manufactur
instruct
mylar
plate
millipor
describ
previous
cellfre
supernat
harvest
kinet
studi
mix
bead
coat
captur
antibodi
variou
cytokin
chemokin
mixtur
incub
biotinyl
detect
antibodi
final
peconjug
streptavidin
ad
fluoresc
signal
measur
use
flexmap
equip
xponent
softwar
luminex
corp
raw
data
measur
mean
fluoresc
intens
mfi
concentr
analyt
calcul
use
logist
fit
curv
gener
analyt
concentr
standard
curv
concentr
analyt
qualiti
control
reagent
found
within
expect
rang
lower
limit
quantif
lloq
determin
use
lowest
point
standard
fit
curv
least
time
background
calcul
lloq
perform
subtract
mfi
background
diluent
mfi
lowest
standard
concentr
backcalcul
concentr
standard
curv
data
analyz
use
prism
softwar
graphpad
softwar
la
jolla
ca
mdm
mddc
plate
black
opaqu
cytotox
assay
clear
bottom
test
viral
inhibit
greiner
micropl
greiner
bioon
monro
nc
cellswel
incub
overnight
drug
powder
formul
dissolv
dmso
millipor
sigma
final
dmso
concentr
lower
drug
solut
dilut
fb
medium
concentr
ad
cellfre
drug
dilut
plate
drug
transfer
drug
dilut
plate
cell
plate
use
liquid
rainin
instrument
oakland
ca
h
prior
infect
duplic
cell
plate
cell
type
infect
merscov
moi
ad
viru
dilut
medium
directli
drug
mixtur
cell
plate
plate
incub
h
cell
cultur
supernat
collect
cell
fix
nbf
collect
supernat
clarifi
centrifug
store
futur
use
quantifi
antivir
activ
candid
compound
cell
base
immunofluoresc
enzymelink
immunosorb
assay
use
describ
previous
fix
plate
describ
stain
rabbit
polyclon
antibodi
protein
sino
biolog
follow
stain
alexa
fluor
goat
antirabbit
igg
hl
antibodi
thermo
fisher
scientif
fluoresc
quantifi
plate
reader
infinit
pro
tecan
us
morrisvil
nc
excit
wavelength
nm
emiss
wavelength
nm
cytotox
assay
perform
parallel
measur
drug
toxic
one
black
opaqu
cell
plate
cell
type
mock
infect
use
medium
condit
infect
cell
cell
viabil
measur
use
celltit
glo
luminesc
cell
viabil
assay
kit
promega
madison
wi
accord
manufactur
instruct
luminesc
read
pro
plate
reader
tecan
antivir
activ
evalu
mean
tissu
cultur
infecti
dose
assay
use
spearmankaerb
method
briefli
serial
dilut
made
cellfre
supernat
sampl
collect
drug
efficaci
evalu
studi
cellbas
enzymelink
immunosorb
assay
dilut
use
infect
vero
cell
plate
seven
infect
well
dilut
sampl
contain
cell
cultur
media
use
neg
control
viru
stock
use
posit
control
test
sampl
ad
well
volum
plate
incub
day
observ
merscovinduc
cytopatholog
follow
incub
media
remov
cell
fix
stain
nbf
contain
crystal
violet
plate
incub
min
room
temperatur
wash
run
water
titer
determin
identifi
endpoint
cytopath
effect
cell
monolay
result
calcul
appli
spearmankaerb
method
present
nonlinear
regress
analysi
perform
calcul
effect
concentr
compound
specif
toxic
cytotox
concentr
use
prism
softwar
graphpad
softwar
doserespons
curv
drug
select
index
si
defin
ratio
concentr
cellular
cytotox
effect
concentr
si
indic
rel
efficaci
compound
viral
replic
inhibit
oppos
caus
cytopath
effect
error
bar
repres
standard
deviat
three
replic
unless
indic
otherwis
statist
signific
determin
perform
use
result
least
two
individu
experi
duplic
triplic
replic
singl
experi
studi
mdm
mddc
care
character
ensur
uniform
reproduc
experi
differenti
mdm
mddc
character
flow
cytometri
perform
previous
mdm
gener
predominantli
hladr
confirm
mdm
popul
highli
purifi
cell
gener
posit
macrophag
fig
phenotyp
human
mddc
show
hladr
dc
matur
marker
present
matur
mddc
fig
compar
immatur
mddc
unstain
control
cell
fig
isol
protocol
use
studi
consist
gener
highli
purifi
phenotyp
homogen
apc
minim
interexperiment
interoper
variabl
determin
primari
apc
permiss
merscov
infect
kinet
studi
perform
measur
viru
titer
follow
infect
use
cell
isol
four
differ
donor
increas
viral
titer
observ
mdm
immatur
mddc
despit
variat
donor
fig
signific
increas
viral
titer
observ
matur
mddc
day
pi
fig
indic
restrict
viru
infect
viru
replic
viru
clearanc
mdm
began
day
pi
viru
could
detect
day
pi
howev
merscov
continu
propag
immatur
mddc
day
pi
demonstr
differenti
infect
replic
capabl
mdm
immatur
mddc
compar
abil
merscov
induc
innat
immun
respons
three
type
apc
releas
cytokin
chemokin
measur
viru
mockinfect
cell
human
panel
includ
antivir
cytokin
proinflammatori
cytokin
chemokin
rant
mdm
merscov
infect
result
increas
concentr
almost
antivir
proinflammatori
cytokin
chemokin
except
mani
cytokin
chemokin
releas
soon
h
pi
fig
may
result
direct
cell
stimul
rather
activ
infect
high
induct
cours
infect
mdm
dramat
indic
strong
antivir
respons
induc
upon
merscov
infect
merscov
infect
repress
express
mdm
repress
decreas
cours
sever
day
fig
similar
respons
profil
seen
chemokin
increas
express
observ
immatur
mddc
fig
howev
bolu
releas
immedi
infect
mddc
releas
cytokin
chemokin
immatur
matur
mddc
neglig
cours
merscov
infect
rel
mockinfect
cell
fig
expect
human
popul
consider
donortodonor
variat
cytokin
respons
observ
follow
infect
merscov
cellbas
immunofluoresc
assay
appli
evalu
antivir
effect
cq
cpz
tomf
mdm
adher
plate
could
fix
stain
cytotox
assay
perform
parallel
use
mockinfect
cell
drug
addit
tomf
perform
well
inhibit
merscov
replic
vero
cell
mdm
activ
tomf
dose
rang
test
low
determin
cytotox
rel
high
fig
unlik
vero
cell
cq
show
detect
antivir
activ
mdm
although
cytotox
associ
compound
fig
cpz
inhibit
merscov
vero
cell
low
cytotox
howev
mdm
cytotox
cpz
rel
high
fig
antivir
activ
cpz
separ
well
cytotox
led
low
select
index
si
cellbas
immunofluoresc
assay
could
appli
immatur
mddc
due
poor
adher
plate
cell
could
fix
antibodi
stain
therefor
efficaci
candid
compound
merscovinfect
apc
evalu
median
assay
matur
mddc
produc
detect
infecti
viru
infect
therefor
exclud
fig
drug
activ
studi
cell
cultur
supernat
save
cellbas
assay
titrat
detect
merscov
evalu
efficaci
compound
viru
yield
reduct
cqtreat
mdm
immatur
mddc
though
cytotox
rel
low
fig
cpz
treat
cell
around
viru
reduct
observ
cell
type
howev
high
cytotox
narrow
therapeut
window
mdm
mddc
fig
viru
reduct
measur
tomftreat
cell
dose
higher
correspond
increas
cytotox
fig
observ
similar
compar
cellbas
assay
mention
viru
yield
reduct
data
tomf
cq
cpz
vero
cell
show
cpz
activ
merscov
infect
drop
drug
dosag
tomf
cq
activ
fig
data
suggest
strong
correl
cell
mdm
viru
titer
determin
sporad
outbreak
mer
continu
occur
current
option
treatment
lifethreaten
zoonot
coronaviru
infect
human
still
lack
lack
treatment
due
poorli
understood
pathogenesi
mer
coronaviru
infect
despit
extens
research
effort
trigger
sar
outbreak
human
apc
cell
mdm
mddc
play
import
role
bridg
innat
adapt
immun
viral
infect
present
viral
antigen
cell
secret
appropri
cytokin
chemokin
mdm
immatur
mddc
resid
site
infect
occur
mucos
surfac
within
respiratori
tract
role
immun
respons
apc
also
potenti
initi
site
viral
replic
addit
apc
act
viral
reservoir
dissemin
organ
alreadi
shown
human
infecti
diseas
like
measl
human
immunodefici
viru
hiv
infect
studi
assess
characterist
merscov
growth
kinet
mdm
mddc
found
merscov
readili
infect
robustli
replic
human
mdm
immatur
mddc
viru
establish
notabl
infect
matur
mddc
high
viral
infect
mdm
immatur
mddc
indic
viru
overcom
initi
antivir
respons
matur
mddc
impart
restrict
prevent
viru
replic
capac
mddc
stimul
cell
close
relat
matur
stage
immatur
dc
highli
special
antigen
uptak
process
poor
stimul
primari
immun
respons
product
infect
immatur
dc
may
delay
activ
cell
therefor
allow
time
merscov
replic
dissemin
addit
reason
immatur
mddc
may
suscept
merscov
infect
matur
mddc
merscov
could
abil
intern
process
viral
antigen
uptak
antigen
pathogen
immatur
mddc
may
undergo
matur
migrat
lymphat
tissu
trigger
adapt
immun
respons
theori
abil
sampl
present
antigen
enhanc
mddc
matur
exampl
immatur
mddc
may
promot
viral
dissemin
sarscov
within
host
recruit
viru
enter
damag
lymphat
tissu
recent
studi
shown
abort
herp
herpesviru
hhv
herp
simplex
infect
matur
mddc
abl
modul
inhibit
tcell
stimulatori
function
endocytosi
matur
dc
slow
somewhat
rel
immatur
dc
potenti
result
chang
endocyt
mechan
receptor
express
similarli
viru
dissemin
system
patient
mer
follow
merscov
infect
induc
immun
respons
apc
consist
suscept
infect
kinet
viru
propag
product
proinflammatori
cytokin
essenti
host
resist
merscov
infect
infect
mdm
merscov
appreci
induc
secret
antivir
cytokin
moder
appreci
upregul
proinflammatori
cytokin
variabl
upregul
inflammatori
chemokin
rant
clinic
studi
shown
express
proinflammatori
cytokineschemokin
highli
correl
diseas
sever
mortal
sar
patient
nichol
et
al
report
macrophag
lung
tissu
sar
patient
identifi
locat
cytokin
storm
viru
pathogenesi
origin
mdm
secret
proinflammatori
cytokin
chemokin
activ
antivir
mechan
may
caus
dysregul
product
inflammatori
mediat
lead
damag
neighbor
tissu
express
potenti
indic
sever
respiratori
viral
infect
sar
human
infect
avian
influenza
virus
data
indic
possibl
ifn
inflammatori
respons
may
caus
sever
mer
diseas
adapt
host
immun
respons
mount
howev
restrict
viru
growth
matur
mddc
result
antivir
activ
nevertheless
moder
express
minim
induct
rant
observ
immatur
mddc
signific
upregul
cytokin
chemokin
observ
either
matur
immatur
mddc
overal
limit
antivir
cytokin
respons
mddc
suggest
possibl
mechan
immun
escap
merscov
infect
seen
sarscov
infect
review
literatur
suggest
signific
gap
knowledg
regard
role
intracellular
regulatori
mechan
pathogen
recognit
receptor
prr
control
coronaviru
infect
studi
essenti
chang
concentr
cytokineschemokin
measur
matur
nonpermiss
mddc
immatur
mddc
measur
concentr
less
control
cell
mani
case
concentr
number
cytokineschemokin
increas
cours
infect
specif
day
titer
highest
data
suggest
prr
may
activ
would
anticip
product
viral
infect
scale
scope
evalu
addit
data
obtain
cytokin
releas
earli
infect
properli
evalu
due
potenti
presenc
cellular
compon
viru
prepar
sever
report
immun
respons
trigger
apc
find
similar
conflict
compar
result
exampl
tynel
et
al
state
merscov
replic
poorli
human
macrophag
monocytederiv
dendrit
cell
stimul
immun
respons
scheuplein
et
al
report
human
macrophag
mddc
mount
immun
respons
follow
merscov
infect
howev
zhou
et
al
found
merscov
infect
robustli
replic
mdm
immatur
mddc
trigger
aberr
product
proinflammatori
cytokinechemokin
respons
discrep
may
relat
differ
experiment
condit
protocol
gener
phenotyp
mdm
mddc
differ
laboratori
variabl
individu
blood
donor
appreci
effort
made
identifi
novel
antivir
therapeut
merscov
sinc
initi
outbreak
occur
compound
target
host
effector
could
benefici
cours
infect
merscov
drug
screen
perform
mostli
establish
cell
line
vero
huh
cell
littl
drug
evalu
perform
primari
cell
line
pick
three
fdaapprov
broadspectrum
inhibitor
cpz
cq
tomf
shown
effect
merscov
infect
immort
cell
line
evalu
antivir
activ
mdm
mddc
exclud
matur
mddc
drug
screen
due
lack
product
merscov
infect
surprisingli
find
tomf
activ
merscovinfect
mdm
immatur
mddc
differ
result
previou
studi
vero
cell
tomf
show
minim
activ
merscov
infect
mdm
tomf
also
littl
antivir
activ
immatur
mddc
reach
high
concentr
associ
high
cytotox
tomf
estrogen
receptor
modul
shown
inhibit
filovirus
block
merscov
sarscov
respect
vero
cell
drug
inhibit
late
phrase
viru
entri
interf
fusion
filovirus
howev
primari
cell
increas
though
lower
cytotox
seen
thu
therapeut
window
effect
treatment
tomf
primari
apc
narrow
previous
cq
wellestablish
antiparasit
agent
show
strong
inhibit
merscov
sarscov
low
rang
low
toxic
cq
like
accumul
lysosom
sequest
proton
increas
ph
drug
interact
varieti
host
protein
cellular
process
result
modul
immun
respons
cq
also
report
inhibit
replic
multipl
virus
flavivirus
influenza
virus
hiv
ebola
nipah
virus
vitro
studi
cq
minim
antim
activ
either
merscovinfect
mdm
immatur
mddc
though
appreci
cytotox
observ
cpz
neurotransmitt
inhibitor
first
antipsychot
drug
develop
treatment
schizophrenia
treatment
cpz
inhibit
clathrinmedi
endocytosi
prevent
formul
clathrinco
pit
plasma
membran
previou
work
report
cpz
inhibit
merscov
infect
huh
cell
vs
primari
cell
activ
merscov
observ
cpzpretreat
mdm
immatur
mddc
howev
high
cytotox
observ
cpz
type
primari
cell
preclud
develop
studi
demonstr
test
compound
shown
efficaci
continu
cell
line
effect
inhibit
merscov
infect
primari
apc
conclus
merscov
infect
primari
mdm
induc
overexpress
inflammatori
cytokineschemokin
potenti
lead
tissu
damag
system
viru
dissemin
hand
mechan
immun
escap
mddc
result
ineffici
viral
clearanc
may
explain
high
pathogen
clinic
manifest
seen
mer
studi
also
provid
first
demonstr
medic
countermeasur
evalu
merscov
primari
apc
illustr
import
use
nonimmort
primari
cell
evalu
drug
efficaci
data
also
suggest
given
establish
mechan
action
tomf
cq
cpz
mechan
viru
intern
exocytosi
may
differ
use
establish
cell
line
perform
vivo
studi
potenti
compound
evalu
primari
cell
major
differ
may
occur
immort
cell
line
primari
cell
